

Table 3. Steady-state pharmacokinetic parameters for moxifloxacin in patients with several pathophysiologic conditions after intravenous or oral drug administration. Values expressed as mean (standard deviation) or mean (range) when standard deviation is not published.

Study characteristics with Moxifloxacin	Vd (L)	Cl (L/h)	T _½ (h)	Reference
Healthy patients				
200 mg oral 33 ± 5 years	222.0 (1.2) ¹	13.1 (0.1) ¹	11.8 (1.2)	Stass et al., 1998 ⁷¹
400 mg oral 18-46 years	175.9 (19.4) ¹	101.0 (2.1) ¹	ND	Grosjean et al., 2012 ⁷²
Morbidly obese patients with a body mass index BMI >40 kg/m²				
400 mg IV 41 ± 12 years	165.0 (30.0)	9.6 (2)	12.2 (2.2)	Keess et al., 2011 ⁷³
Hospitalized patients with severe liver insufficiency and pneumonia or spontaneous bacterial peritonitis				
400 mg IV 40-78 years	154.1 (118.5-216.1)	8.8 (6.4-10.5)	10.4 (8.5-16.0)	Barth et al., 2008 ⁹⁶
Outpatients with pneumonia receiving hemodialysis				
400 mg oral 47-78 years	ND	6.5 (1.9) ¹	ND	Takamatsu et al., 2017 ⁹⁸
Critically ill patients receiving continuous hemodiafiltration				
400 mg IV 25-76 years	266.0 (154-514)	15.7 (8.1-49.39)	12.3 (3.7-34.0)	Czock et al., 2006 ⁹³

**Intensive care unit
patients**

with COPD²

115.0 (40.0)

8.85 (2.6)

9.7 (3.7)

Sionidou et al., 2019⁹⁷

400 mg IV

70 ± 10 years

Vd: Volume of distribution in steady state, Cl: Systemic clearance, IV: Intravenous administration, BMI: Body mass index, defined as body weight [in kilograms]/ height² [in meters], Cl_{Cr}= Creatinine clearance, ND: Unpublished data.

¹Value of apparent volume of distribution in steady state (Vd/F) and apparent clearance (Cl/F) respectively

²COPD: Chronic Obstructive Pulmonary Disease